Brookline Capital Upgrades Outlook Therapeutics to Buy, Announces $1.57 Price Target
Portfolio Pulse from Benzinga Newsdesk
Brookline Capital analyst Kemp Dolliver has upgraded Outlook Therapeutics (NASDAQ:OTLK) from Hold to Buy and set a price target of $1.57.
January 25, 2024 | 10:41 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Outlook Therapeutics' stock rating has been upgraded by Brookline Capital from Hold to Buy with a new price target of $1.57.
Analyst upgrades typically lead to a positive short-term reaction in the stock market as they suggest improved prospects for the company. The new price target of $1.57 indicates a potential upside from the current trading price, which may attract investors and drive up the stock price.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100